Supplemental Guidance Related to Improving Drug Utilization Review Controls in Part D
Guidance for the section entitled, “Improving Drug Utilization Review Controls in Part D,” of the Final CY 2013 Call Letter, which sets forth how Medicare Part D sponsors can comply with drug utilization management (DUM) requirements of 42 C.F.R 423.153 et seq. to prevent overutilization of prescribed covered Part D drugs.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: August 31, 2012
HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.